A Top UK Midcap Performer’s US Plans Help it Evade Tariff Glare
Technicians at Oxford BioMedica in Oxford.
Photographer: Heathcliff O’Malley/AFP/Getty ImagesA provider of cell and gene therapy services is among the best performers in Britain’s midcap stock gauge this quarter, helped by a growing US manufacturing presence that has kept it away from the glare of President Donald Trump’s tariffs regime.
Shares in Oxford Biomedica Plc, which counts AstraZeneca Plc and Novartis AG among its clients, have surged 76% so far this quarter. That’s the second-best performance in the UK’s FTSE 250 Index, in which the stock recently regained its place.